Organisation paid for research Program year 2024 Source: CMS Open Payments

Accel Research Site Neurostudies

Neither a doctor nor a teaching hospital

Research payments

$571,992

7 payments

Through program year 2024, Accel Research Site Neurostudies is reported as receiving $571,992 in research payments, across 7 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$405,340	5
2023	Research	$166,652	2

Breakdown

Who paid Research payments · program years 2023–2024

Vertex Pharmaceuticals Incorporated $571,992 7 payments

Studies the money was for Research payments · program years 2023–2024

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy $339,465 2 payments
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $167,004 2 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $34,329 1 payment
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $19,308 1 payment
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $11,887 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.